Carl Icahn
Carl Icahn is a billionaire financier, ranking #18 on the 2007 Forbes 400 list with an estimated net worth of $14.5 billion.
Icahn built a name for himself in the 1980s as a corporate raider. After keeping quite for years, Icahn made a major comeback as a 'activist investor'. An activist investor agitates companies for changes, including buyouts, share buybacks, and dividend increases.
Icahn has successfully pushed for changes at Time Warner (NYSE: TWX) and Temple-Inland (NYSE: TIN), among others. Icahn won board seats at Motorola (NYSE: MOT) after first failing.
In 2007, Icahn's activism successfully pushed biotech company MedImmune into a sales agreement with AstraZeneca (NYSE: AZN). Icahn is also involved with biotech company Imclone Systems (Nasdaq: IMCL), where he is Chairman of the Board.
In early, 2008 Icahn activist target BEA Systems (Nasdaq: BEAS) was sold to Oracle (Nasdaq: ORCL). Icahn held a 13% stake in BEA.
Icahn is also involved with developments at Biogen Idec (Nasdaq: BIIB) and WCI Communities (NYSE: WCI), which both unsuccessfully explored sales. WCI rejected a $22 per share takeover offer from Icahn in early 2007, only to see its stock plummet on the housing slowdown.
In 2008, Icahn targeted Yahoo! (Nasdaq: YHOO) after the Internet company failed to work out an acceptable merger agreement with Microsoft (Nasdaq: MSFT) Microsoft walked away from its bid for Yahoo! after months of bickering.
View Older Stories View More Recent Stories
-
Commercial Metals (CMC) Adopts Shareholder Rights Plan Following Icahn Ownership Increase
-
Commercial Metals (CMC) volatility elevated on Icahn reporting 9.98% stake
-
Icahn Raises Stake in Commercial Metals Co. (CMC) to 9.98%
-
Carl Icahn shows 9.98% stake in Commercial Metals Company (CMC)
-
Clorox (CLX) Rejects Icahn's Offer
-
UBS Maintains a 'Neutral' on Clorox (CLX); More Thoughts on Icahn’s $80 Bid
-
Motorola Mobility (MMI) Issues Statement on Icahn's 13D Filing
-
Icahn Says Motorola (MMI) Should Explore Alternatives for Patent Portfolio
-
Clorox (CLX) Confirms Receipt of Revised Offer from Icahn, to Review Proposal
-
Icahn Sweetens Bid for Clorox (CLX) to $80/Share; Says 'Let Shareholders Decide'
-
Pre-Open Movers 7/20: (NLC) (ETFC) (AAPL) Higher; (DVAX) (RVBD) (ICGN) Lower (more...)
-
Icahn boosts bid for Clorox (CLX) to $80 per share in cash
-
Jefferies Lifts Price Target on and Estiamtes On Forest Laboratories (FRX)
-
Clorox (CLX) Formally Rejects Bid from Carl Icahn
-
UBS Maintains a 'Neutral' on Clorox (CLX); Assessing "The Icahn Effect"
-
Top 10 News Items 7/11-7/15: Fed's Latest Minutes Hint at QE3; Google Issues Blowout Q2 Earnings; Moody's, S&P Place US AAA Rating on Watch for Downgrade
-
Carl Icahn Doesn't Want Clorox (CLX), He Wants Procter & Gamble (PG) to Buy It
-
Carl Icahn Coming On CNBC To Discuss Clorox (CLX) Offer
-
Notable Mergers and Acquisitions of the Day 07/151: (CLX) (HK)/(BHP) (ICE)
-
Morning Movers 07/15: (HK) (GOOG) (COG) (CLX) Higher; (FLIR) (PPHM) (DCTH) (QLIK) Lower
-
Pre-Open Movers 7/15: (HK) (GOOG) (CLX) Higher; (FLIR) (SGEN) (RAH) Lower (more...)
-
Clorox (CLX) volatility elevated at 20 into Icahn offering $76.50 per share
-
Clorox (CLX) Confirms $76.50/Share Bid from Icahn, to Review Offer
-
Clorox (CLX) Higher as Icahn Discloses $76.50/Share Takeover Bid
-
Benchmark Maintains a 'Sell' on Oshkosh (OSK) on Further Defense Downside; Potential Q3 Miss in Late July
-
Unusual 11 Mid-Day Movers 07/01: (TBSI) (CAMP) (IDCC) Higher; (AUTC) (DMAN) (EK) Lower
-
Oshkosh (OSK) Says 9.51% Icahn Stake 'Real'
-
After Hours Movers 6/30: (OSK) (AREX) (APOL) (DNDN) (KBH) Higher; (EK) (WLT) Lower
-
Oshkosh (OSK) Ramps 7% on New Carl Icahn Stake
-
Icahn Capital Shows New 9.51% Stake in Oshkosh Corp. (OSK)
-
Carl Icahn shows Oshkosh Corporation (OSK) stake
-
Carl Icahn Amends 'Item 3' in 13D on Forest Labs (FRX)
-
Forest Labs (FRX) Shares on the Move as Co. Hires Advisers to Help Defend Against Icahn
-
Icahn Capital Lowers Stake in Biogen Idec, Inc. (BIIB) to 3.4%
-
Collins Stewart Raises Price Target on Forest Laboratories (FRX) Following Carl Icahn's 13D Filing
-
Forest Labs (FRX) Shares Rising as Icahn Discloses Purchase of Calls, May Continue to Seek Talks with Mgmt; Shows 6.95% Stake
-
Notable 52-Week Highs and Lows of the Day 06/13: (ORS) (INSM) (FRX) High; (NOK) (RIMM) (BZH) Low
-
Carl Icahn Seeks Four for Forest Laboratories (FRX) Board
-
Hain Celestial (HAIN) Has the Right Gluten-Free Ingredients for Gains - Cramer
-
Carl Icahn Sells 5M Take-Two Interactive (TTWO) Shares
-
Comments from Hedge Fund Managers at Ira Sohn Conference Could Move Markets; Ackman, Einhorn, Icahn, Falcone, Eisman to Speak
-
Call Icahn Dumps Over 2 Million Biogen Idec (BIIB) Shares
-
Carl Icahn Sells Biogen Idec (BIIB) Shares
-
Icahn's Icahn Capital Shows New Stake in Amgen (AMGN), Clorox (CLX) and Southern Union (NYSE: SUG); Raises Dynegy (DYN), Lowers Chesapeake (CHK)
-
DA Davidson Reiterates a 'Buy' on Mentor Graphics (MENT); Positive Trends To Continue
-
Mentor Graphics (MENT) Jumps After Icahn Wins Three Board Seats
-
Icahn's Icahn Capital Shows 7.03% Stake in Cyberonics (CYBX)
-
Mentor Graphics (MENT) Issued Open Letter to Shareholders
-
Icahn Issues Letter to Shareholders of Mentor Graphics (MENT)
-
Canaccord Genuity Morning Coffee on Dish Network (DISH): New Addition
